New Evidence Available
Updated Recommendation
A new evidence synthesis was published:2020, WHO consolidated guidelines on tuberculosis: tuberculosis preventive treatment: Module 1: prevention
View latest version (2020)Bibliographic information
GuidelineLatent tuberculosis infection: updated and consolidated guidelines for programmatic management
Year of Publication2018
Issuing InstitutionWHO
Recommendation
Retired
The following options are recommended for treatment of LTBI in countries with a low TB incidence as alternatives to 6 months of isoniazid monotherapy: 9 months of isoniazid, or a 3-month regimen of weekly rifapentine plus isoniazid, or 3–4 months of isoniazid plus rifampicin, or 3–4 months of rifampicin alone
Recommended in favor
Strong
Certainty of evidence
Moderate
Notes and Remarks
Rifampicin- and rifapentine-containing regimens should be prescribed with caution to people living with HIV who are on ART because of potential drug–drug interactions.